Results 51 to 60 of about 208,685 (341)

Cardiac hypertrophy and heart failure: from the case to review of literature [PDF]

, 2016
In response to an increased workload due to physiological or pathological stimuli, the heart may undergo a process of growth with increased muscle mass called cardiac hypertrophy. It is a particular mechanism of long term compensation used by the heart
Massoni, Francesco, Onofri, Emanuela, Ricci, Lidia, Ricci, Serafino, Simeone, Claudio   +4 more
core   +1 more source

Targeting Adipose Tissue Function Protects Against Heart Failure with Preserved Ejection Fraction

Advanced Science, EarlyView.
This study explores the role adipose tissue (AT) phenotypes have in determining cardiovascular outcomes in an obesity‐related heart failure with preserved ejection fraction (HFpEF) model. Pharmacological induction of thermogenesis promoted resilience to HFpEF‐induced remodeling of AT and conferred cardioprotection. Surgical and genetic models confirmed
Jordan Jousma, Zhenbo Han, Jooman Park, Gege Yan, Sen Zhang, Youjeong Kwon, Sarath Babu Nukala, Jindpreet Kandola, Sandra Pinho, Chong Wee Liew, Yuwei Jiang, Sang‐Ging Ong   +11 more
wiley   +1 more source

A Unique High‐Output Cardiac Hypertrophy Phenotype Arising From Low Systemic Vascular Resistance in Cantu Syndrome

Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, 2022
Background Cardiomegaly caused by left ventricular hypertrophy is a risk factor for development of congestive heart failure, classically associated with decreased systolic and/or diastolic ventricular function.
Gautam K. Singh, Conor McClenaghan, Manish Aggarwal, Hongjie Gu, Maria S. Remedi, Dorothy K. Grange, Colin G. Nichols   +6 more
doaj   +1 more source

Fibroblast Growth Factor–23 and Cardiac Structure and Function [PDF]

, 2014
Background: Fibroblast growth factor–23 (FGF‐23) is a phosphaturic factor previously associated with left ventricular hypertrophy and systolic dysfunction among individuals with chronic kidney disease.
Agarwal, Isha, Ide, Noriko, Ix, Joachim H., Kestenbaum, Bryan, Lanske, Beate, Mukamal, Kenneth J., Schiller, Nelson B., Whooley, Mary A.   +7 more
core   +1 more source

Inactivation of AXL in Cardiac Fibroblasts Alleviates Right Ventricular Remodeling in Pulmonary Hypertension

Advanced Science, EarlyView.
Pulmonary hypertension (PH) is a progressive condition with high morbidity and mortality, largely owing to right ventricular (RV) failure resulting from maladaptive remodeling. Our study provides strong evidence in support of a critical, detrimental role for AXL as a previously unrecognized determinant driving RV fibrotic pathology in PH.
Li‐Wei Wu, Min Chen, Chen‐Yu Jiang, Dai‐Ji Jiang, Xu Zhang, Xiao‐He Xu, Yi‐Wei Liu, Bei Feng, Lin‐Cai Ye, Yang‐Yang He, Xu Huang, Yi‐Chi Zhang, Xing‐Liang Zhou, Yi Shen, Tian‐Yu Liu, Li‐Jun Fu, Yi Yan, Hao Zhang   +17 more
wiley   +1 more source

Muscleblind-like 3 deficit results in a spectrum of age-associated pathologies observed in myotonic dystrophy. [PDF]

, 2016
Myotonic dystrophy type I (DM1) exhibits distinctive disease specific phenotypes and the accelerated onset of a spectrum of age-associated pathologies.
Abdallah, Walid F, Choi, Jongkyu, Comai, Lucio, Dansithong, Warunee, Dixon, Donald M, Jordan, Maria C, Lee, Han Shin, Reddy, Sita, Roos, Kenneth P, Trac, Brandon   +9 more
core   +1 more source

Redox‐Responsive Tellurium‐Bridged Covalent Organic Frameworks/PEG Composites for Targeted Therapy of Diabetic Cardiomyopathy

Advanced Science, EarlyView.
This study unlocks the immense potential of COF@polymer nanocomposites as a multifunctional therapeutic platform for targeted drug delivery in diabetic cardiomyopathy. Abstract Diabetic cardiomyopathy, a major complication of diabetes, is strongly associated with elevated levels of glycated hemoglobin (HbA1c) and reactive oxygen species (ROS). However,
Jing Xue, Jialu Zhuang, Taotao Fan, Songtao Tang, Junjun Wang, Xiaohui Liu, Jian Liu, Jin Shi, Jiaji Li, Wanjun Li, Danyou Hu, Xiaoqian Zhang, Hua Wang, Guiyang Zhang   +13 more
wiley   +1 more source

Left ventricular hypertrophy.

Australian family physician, 1991
Long-lasting cardiac overload in man as well as in experimental animals leads to an increase in heart weight (or better: heart weight/body weight ratio). Cardiac hypertrophy can result from increased physiologic activity (“physiologic hypertrophy”) or from disease states (“pathologic hypertrophy”).
C, McRae, N, Carson
  +7 more sources

The effect of Valsalva maneuver on diastolic filling indices in patients with essential hypertension.

مجلة كلية الطب, 2010
Background: Left ventricular hypertrophy and diastolic dysfunction are considered to be an important risk factor for cardiovascular morbidity and mortality in asymptomatic hypertensive patients.
Salam A. Mahdi, Najeeb H. Mohammed, Hilal B. AL-Saffar   +2 more
doaj   +1 more source

Serum Zinc and Selenium Concentrations in Patients with Hypertrophy and Remodelling of the Left Ventricle Secondary to Arterial Hypertension

Antioxidants, 2021
The aim of the study was to assess the relationship between serum selenium and zinc concentrations (Se-S and Zn-S) and the left ventricle geometry in patients suffering from arterial hypertension. A total of 78 people with arterial hypertension (mean age:
Paweł Gać, Karolina Czerwińska, Małgorzata Poręba, Adam Prokopowicz, Helena Martynowicz, Grzegorz Mazur, Rafał Poręba   +6 more
doaj   +1 more source